Vernakalant
As of the edition of 20 October 2026, Vernakalant is a small molecule: marketed, first approved in 2010 (EU); acts on KCNA5, KCND3 and KCNH2 and 3 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Small molecule
- Brand name
- Brinavess
- First approved
- 1 September 2010 (EU)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Cipher Pharmaceuticals; 2 holders in all
- Registered trials
- 13, 2 stopped early
- Disease areas
- Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
5 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product5 company-target rows are on route B because of Vernakalant.
See the 5 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| KCNA5 | Potassium voltage-gated channel subfamily A member 5 | P22460 |
| KCNJ5 | G protein-activated inward rectifier potassium channel 4 | P48544 |
| KCNJ3 | G protein-activated inward rectifier potassium channel 1 | P48549 |
| KCNH2 | Voltage-gated inwardly rectifying potassium channel KCNH2 | Q12809 |
| SCN5A | Sodium channel protein type 5 subunit alpha | Q14524 |
| KCND3 | A-type voltage-gated potassium channel KCND3 | Q9UK17 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 9 | 7 | 1 | 1 |
| Phase 4 | 1 | 0 | 0 | 1 |
| All trials | 13 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Advanz Pharma | Acquired holder and Lead sponsor of trials | 2003 to now |
| Cipher Pharmaceuticals | Applicant | 2017 to now |